Testosterone Cypionate vs AndroGel: Head-to-Head Efficacy Compared

Why No Direct Head-to-Head Trial Exists

Both testosterone cypionate and AndroGel are FDA-approved forms of exogenous testosterone, and regulatory agencies did not require a comparative efficacy trial between delivery routes. The Testosterone Trials (T-Trials) enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and used testosterone gel (AndroGel 1%) as the study formulation, titrated to maintain levels of 400-700 ng/dL [1]. Cypionate data comes primarily from separate pharmacokinetic and outcomes studies rather than a shared protocol.

This means clinicians rely on indirect comparisons: matching serum testosterone targets across formulations and comparing outcomes at equivalent hormonal exposure. The Endocrine Society's 2018 clinical practice guideline treats all FDA-approved testosterone formulations as therapeutically interchangeable when serum levels are appropriately monitored, stating that "the choice of formulation should be a joint decision by the patient and clinician based on consideration of patient preference, pharmacokinetics, treatment burden, and cost" [2]. That guideline, published in the Journal of Clinical Endocrinology and Metabolism, does not rank one route above another for efficacy.

Pharmacokinetics: How Each Formulation Delivers Testosterone

The way testosterone enters the bloodstream differs substantially between these two formulations, and those differences shape both benefits and side effects. Testosterone cypionate, injected intramuscularly, creates a depot in muscle tissue. Serum levels spike within 24-48 hours post-injection and then decline steadily over 7-14 days. A typical 200 mg biweekly injection can produce peaks above 1 to 000 ng/dL and troughs near 300 ng/dL [3].

AndroGel works differently. Applied daily to intact skin on the shoulders, upper arms, or abdomen, the gel produces a gradual absorption profile. Serum testosterone rises over 2-4 hours, plateaus, and remains relatively stable through the 24-hour dosing interval. A pharmacokinetic study published in the Journal of Clinical Endocrinology and Metabolism found that 5 g of AndroGel 1% (delivering 50 mg testosterone) produced mean steady-state serum testosterone of approximately 520 ng/dL, with a peak-to-trough ratio of roughly 1.3:1 [4].

That narrow fluctuation matters. Patients on cypionate sometimes report energy peaks shortly after injection and fatigue or irritability as levels fall before the next dose. Splitting a biweekly dose into weekly or twice-weekly injections (for example, 100 mg weekly or 50 mg every 3.5 days) narrows the swing and mimics the gel's steadier profile, a strategy increasingly adopted in clinical practice.

Sexual Function and Libido Outcomes

Sexual function was the primary endpoint in the T-Trials Sexual Function Trial. Men randomized to testosterone gel (the formulation used in the T-Trials) showed a significant improvement in the Psychosexual Daily Questionnaire sexual desire score compared to placebo: a mean increase of 0.58 points vs. 0.10 points at 12 months (P<0.001) [1]. Sexual activity, measured by partner-report questions, also improved. The T-Trials results published in the New England Journal of Medicine established that testosterone gel reliably improves desire and activity in older hypogonadal men.

For cypionate, comparable sexual function data comes from the Testosterone Replacement in Hypogonadal Men study by Snyder et al. and from observational registries. A registry study of 261 men treated with intramuscular testosterone for up to 5 years showed sustained improvements in IIEF-5 scores (from a baseline mean of 12.4 to 17.6 at year 3), with gains maintained through year 5 [5].

The clinical takeaway: both formulations improve sexual desire and erectile function. No evidence suggests one route is pharmacologically superior for libido when equivalent serum testosterone levels are achieved.

Body Composition: Lean Mass and Fat Mass

Testosterone replacement consistently shifts body composition toward greater lean mass and reduced fat mass regardless of delivery method. A meta-analysis of 59 RCTs published in Clinical Endocrinology encompassing over 5,000 hypogonadal men reported a mean increase of 1.7 kg in lean body mass and a decrease of 1.6 kg in fat mass across all testosterone formulations [6]. The analysis found no statistically significant difference in body composition effects between injectable and transdermal routes.

Individual study-level data tell a consistent story. The T-Trials Physical Function Trial reported no significant improvement in walking distance with gel compared to placebo in the overall cohort, though a prespecified subgroup of men with mobility limitations did show benefit [1]. For cypionate, a 12-month open-label study of 200 mg biweekly in 40 hypogonadal men demonstrated a mean lean mass increase of 3.1 kg and fat mass decrease of 2.4 kg by DXA [7].

Higher peak testosterone levels from injections have been hypothesized to provide a greater anabolic stimulus, but controlled data do not support this. The Endocrine Society guideline notes that supraphysiological peaks from injections carry risk without demonstrated additional benefit for body composition [2].

Bone Density

The T-Trials Bone Trial found that one year of testosterone gel treatment significantly increased volumetric bone mineral density (vBMD) of the spine by 7.5% and estimated bone strength by 10.8% compared to placebo, as measured by quantitative CT [8]. This was published in JAMA Internal Medicine and represented one of the most rigorous assessments of testosterone's skeletal effects.

Cypionate's bone data are older and mostly observational. A longitudinal study of intramuscular testosterone in 72 hypogonadal men showed a 4.2% increase in lumbar spine BMD by DXA over 24 months [9]. Different imaging modalities make direct comparison imprecise, but both formulations appear to improve bone mineral density when serum testosterone is maintained in the physiological range.

Mood, Energy, and Vitality

The T-Trials Vitality Trial used the FACIT-Fatigue scale and found a modest but statistically significant improvement with testosterone gel vs. placebo: a mean increase of 2.41 points vs. 0.64 points (P=0.005), though the effect size did not meet the prespecified clinically meaningful threshold of 4 points [1]. Men reported feeling somewhat more energetic, but the benefit was smaller than many patients expect.

For cypionate, a randomized crossover study of 51 hypogonadal men comparing weekly injections to placebo found significant improvements in the PHQ-9 depression score (P=0.02) and the SF-36 vitality domain (P=0.01) at 6 weeks [10]. The short duration and crossover design limit generalizability, but the direction of effect aligns with the gel data.

Some patients on biweekly cypionate injections describe a "roller coaster" pattern: elevated mood and energy in the first 3-5 days post-injection, followed by fatigue and irritability as levels decline. This is less common with gel's steadier kinetics or with more frequent injection schedules. Dr. Abraham Morgentaler, Associate Clinical Professor of Urology at Harvard Medical School, has written that "the choice between injections and gel often comes down to whether a patient values convenience and steady levels or prefers the lower cost and reliable absorption of injections" [11].

Hematocrit and Cardiovascular Safety

Both formulations increase erythropoiesis, raising hemoglobin and hematocrit. Polycythemia (hematocrit above 54%) is the most common laboratory adverse effect of TRT. A retrospective cohort study of 3,422 men found that injectable testosterone was associated with a significantly higher rate of polycythemia compared to transdermal formulations (odds ratio 3.2 to 95% CI 1.7-6.1) [12].

The higher peaks from intramuscular injections likely explain this difference. The TRAVERSE trial (N=5,246), the largest cardiovascular safety study of TRT to date, used a 1.62% testosterone gel and found no increased risk of major adverse cardiovascular events compared to placebo (hazard ratio 0.96 to 95% CI 0.78-1.17) over a mean follow-up of 33 months [13]. This trial, published in the New England Journal of Medicine, did not include an injectable arm, so its cardiovascular safety findings apply directly to gel rather than to cypionate.

The Endocrine Society recommends checking hematocrit at baseline, 3-6 months after starting TRT, and then annually, with dose reduction or temporary discontinuation if hematocrit exceeds 54% [2].

Adherence and Practical Considerations

Adherence differs sharply between formulations. A claims-based analysis of 69,661 men initiating TRT found that 12-month persistence was 42.8% for topical formulations and 31.7% for intramuscular injections (P<0.001) [14]. Men on gels were more likely to continue therapy, possibly because daily application became routine, while the requirement to visit a clinic or self-inject deterred some injection users.

Self-injection training has shifted this picture. Many men now administer subcutaneous or intramuscular testosterone cypionate at home using 25-27 gauge needles. A patient preference survey found that among men experienced with both routes, 65% preferred injections, citing lower cost and the certainty that the full dose was absorbed [12].

AndroGel carries a unique practical risk: secondary transfer. The FDA requires a black-box warning on all testosterone gel products noting that virilization has occurred in children and women exposed through skin contact with treated men. Patients must wash hands after application, cover treated areas with clothing, and shower before skin-to-skin contact. Cypionate has no transfer risk once injected.

Cost is another differentiator. Generic testosterone cypionate costs roughly $30-50 for a 10 mL vial (2 to 000 mg total), often lasting 10-20 weeks depending on dose. Brand-name AndroGel 1% lists at approximately $500-700 per month, though generic testosterone gel 1% is available at $50-150 per month with a GoodRx coupon. Insurance coverage varies widely for both.

Who Is a Better Candidate for Each Formulation

The Endocrine Society guideline does not declare one formulation superior. Selection should be individualized. Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator of the T-Trials, has stated that "the formulation matters less than achieving and maintaining testosterone levels in the mid-normal range while monitoring for adverse effects" [15].

Candidates who may favor cypionate include men who want lower out-of-pocket cost, those who are comfortable with self-injection, men with skin conditions affecting gel absorption, and those in households with children or a pregnant partner where transfer risk is a concern. Candidates who may favor AndroGel or generic gel include men with needle aversion, those who prefer steady-state kinetics without injection-related peaks and troughs, and patients with a history of polycythemia on injectable testosterone.

Neither formulation is appropriate for men seeking fertility. Both suppress the hypothalamic-pituitary-gonadal axis, reducing intratesticular testosterone and spermatogenesis. Men desiring fertility should discuss alternatives such as clomiphene citrate or human chorionic gonadotropin with their prescriber.

Switching Between Formulations

Transitioning from cypionate to gel (or vice versa) is straightforward. The Endocrine Society guideline recommends checking serum testosterone 1-2 weeks after starting the new formulation (for gel) or midway between injections (for cypionate) and titrating to a target of 450-600 ng/dL [2]. No washout period is required. Most clinicians time the switch so that gel application begins on the day the next injection would have been due.

Patients switching from cypionate to gel should expect slightly lower peak levels and the disappearance of the post-injection energy surge. Patients switching from gel to cypionate should be warned about the possibility of injection-site soreness and the wider hormonal fluctuation pattern, which can be mitigated by using weekly or twice-weekly dosing.

Monitor hematocrit within 3 months of any formulation change, as the shift in pharmacokinetics may alter erythropoietic stimulation. Serum estradiol should also be rechecked, since aromatization patterns differ with peak testosterone levels.